The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.
 
Mitchell Reed Smith
Honoraria - Acrotech Biopharma; CytomX Therapeutics; Kite, a Gilead Company; Pharmacyclics/Janssen
Speakers' Bureau - Acrotech Biopharma; AstraZeneca
 
Opeyemi Jegede
No Relationships to Disclose
 
Peter Martin
Consulting or Advisory Role - Bayer; BeiGene; Celgene; Cellectar; I-Mab; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Kite/Gilead; MorphoSys; Regeneron; Sandoz; TeneoBio; Verastem
Research Funding - Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Janssen
 
Brian G. Till
Research Funding - MustangBio (Inst)
Patents, Royalties, Other Intellectual Property - Patent and royalties for a CD20-targeted chimeric antigen receptor from Mustang Bio
 
Samir S. Parekh
No Relationships to Disclose
 
David T Yang
No Relationships to Disclose
 
Lale Kostakoglu
Honoraria - Novartis
Consulting or Advisory Role - BeiGene; ImaginAb; Roche/Genentech
Travel, Accommodations, Expenses - Roche
 
Carla Casulo
Honoraria - Gilead Sciences
Research Funding - Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Roche
 
Nancy L. Bartlett
Consulting or Advisory Role - Acerta Pharma; ADC Therapeutics; BTG; Roche/Genentech; Seagen
Research Funding - ADC Therapeutics (Inst); Affimed Therapeutics (Inst); Autolus (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Paolo Fabrizio Caimi
Consulting or Advisory Role - ADC Therapeutics; Amgen; Bayer; Epizyme; Kite, a Gilead company; Verastem
Speakers' Bureau - Celgene
Patents, Royalties, Other Intellectual Property - XaTEC patent holder (I)
 
Tareq Al Baghdadi
Stock and Other Ownership Interests - Array BioPharma; AstraZeneca; Biogin; Bristol-Myers Squibb; Celgene; Epizyme; HERON; Portola Pharmaceuticals; Seagen; Spectrum Pharmaceuticals; Sunesis Pharmaceuticals; TRACON Pharma
Honoraria - Cardinal Health
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; Kite, a Gilead company; MorphoSys
Travel, Accommodations, Expenses - Abbvie/Genentech; Bristol-Myers Squibb; Cardinal Health
 
Kami J. Maddocks
Honoraria - ADC Therapeutics; BMS; Celgene; Genmab; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Pharmacyclics; Seagen
Research Funding - Bristol-Myers Squibb; Merck; Pharmacyclics
 
Mark D. Romer
No Relationships to Disclose
 
David James Inwards
Research Funding - Acerta Pharma (Inst)
 
Rachel E. Lerner
No Relationships to Disclose
 
Lynne I. Wagner
Stock and Other Ownership Interests - Gilead Sciences (I); Johnson & Johnson (I); Lilly (I)
Consulting or Advisory Role - Athenex; Celgene
Travel, Accommodations, Expenses - Celgene
 
Richard F. Little
No Relationships to Disclose
 
Jonathan W. Friedberg
Consulting or Advisory Role - Astellas Pharma; Novartis
Research Funding - Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Patient on bone marrow microenvironment signals (I)
 
John Paul Leonard
Consulting or Advisory Role - Abbvie; ADC Therapeutics; Akcea Therapeutics; AstraZeneca; Bayer; Bayer; Bristol-Myers Squibb; Celgene; Epizyme; Genentech/Roche; Genmab; Gilead Sciences; Incyte; Karyopharm Therapeutics; MEI Pharma; Merck; Miltenyi Biotec; Morphosys; Nordic Nanovector; Nordic Nanovector; Regeneron; Sandoz; Sutro Biopharma
Research Funding - Alliance for Clinical Trials in Oncology (Inst); Celgene (Inst); Epizyme (Inst); Janssen Oncology (Inst); National Cancer Institute (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - BeiGene
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Genentech; Incyte; Janssen; Karyopharm Therapeutics; Kite/Gilead; MEI Pharma; Molecular Templates; MorphoSys; Pharmacyclics; Pharmacyclics; Roche; Teva
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Celgene (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Abbvie; Celgene; Genentech/Roche; Juno Therapeutics; Millennium; Seagen